We are pleased to announce the successful DCP approval for Eribulin solution for injection, 0.44mg/ml.
Our product has been developed based on the reference brand Halaven and is indicated in the treatment of Liposarcoma and Metastatic breast cancer. The product sold at $325mio globally in 2022, according to IQVIA.
Eribulin, a synthetic analogue of halichondrin B, undergoes a complex synthesis process comprising 73 intricate steps, necessitating cutting-edge technology for successful execution. Furthermore, the compound's sensitivity to light, humidity, and heat poses challenges in developing a stable final product.
As of today, there are no generic MA’s granted for this product. We will now progress with launch of this product on day-1, after the expiry of relevant IP rights.
This positive news further showcases our ability to bring complex products to our partners, with a competitive approach.
Partner up Now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com- LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force